JPH02673B2 - - Google Patents

Info

Publication number: JPH02673B2
Authority: JP; Japan
Prior art keywords: hepatitis; antigen; antibody; solid support; antibodies
Prior art date: 1978-03-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP54024607A

Other languages

English (en)

Japanese (ja)

Other versions

JPS54128396A (en

Inventor

Henrii Detsukaa Richaado

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-03-20

Filing date

1979-03-05

Publication date

1990-01-09

1979-03-05 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

1979-10-04 Publication of JPS54128396A publication Critical patent/JPS54128396A/ja

1990-01-09 Publication of JPH02673B2 publication Critical patent/JPH02673B2/ja

Status Granted legal-status Critical Current

Links

239000000427 antigen Substances 0.000 claims description 58
102000036639 antigens Human genes 0.000 claims description 58
108091007433 antigens Proteins 0.000 claims description 58
239000007787 solid Substances 0.000 claims description 32
208000002672 hepatitis B Diseases 0.000 claims description 21
238000000034 method Methods 0.000 claims description 21
208000005252 hepatitis A Diseases 0.000 claims description 18
239000003153 chemical reaction reagent Substances 0.000 claims description 16
239000007790 solid phase Substances 0.000 claims description 15
238000012360 testing method Methods 0.000 claims description 14
235000000346 sugar Nutrition 0.000 claims description 11
208000006454 hepatitis Diseases 0.000 claims description 5
231100000283 hepatitis Toxicity 0.000 claims description 5
101710132601 Capsid protein Proteins 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000011324 bead Substances 0.000 claims description 3
239000011521 glass Substances 0.000 claims description 3
230000001900 immune effect Effects 0.000 claims description 3
239000004033 plastic Substances 0.000 claims description 3
229920003023 plastic Polymers 0.000 claims description 3
239000002184 metal Substances 0.000 claims description 2
229910052751 metal Inorganic materials 0.000 claims description 2
239000003463 adsorbent Substances 0.000 claims 2
239000004698 Polyethylene Substances 0.000 claims 1
238000001035 drying Methods 0.000 claims 1
-1 polyethylene Polymers 0.000 claims 1
229920000573 polyethylene Polymers 0.000 claims 1
239000002245 particle Substances 0.000 description 12
238000003127 radioimmunoassay Methods 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
239000000243 solution Substances 0.000 description 11
238000001514 detection method Methods 0.000 description 10
239000000523 sample Substances 0.000 description 10
239000004793 Polystyrene Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
229920002223 polystyrene Polymers 0.000 description 9
238000003018 immunoassay Methods 0.000 description 8
229930006000 Sucrose Natural products 0.000 description 7
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
239000011248 coating agent Substances 0.000 description 7
238000000576 coating method Methods 0.000 description 7
239000005720 sucrose Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000013642 negative control Substances 0.000 description 6
239000000463 material Substances 0.000 description 5
239000008188 pellet Substances 0.000 description 5
150000008163 sugars Chemical class 0.000 description 5
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
239000004816 latex Substances 0.000 description 4
229920000126 latex Polymers 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000012266 salt solution Substances 0.000 description 4
238000009495 sugar coating Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000004520 agglutination Effects 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000009137 competitive binding Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000013610 patient sample Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000010998 test method Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000037319 Hepatitis infectious Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
208000037048 Prodromal Symptoms Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000012817 gel-diffusion technique Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000005976 liver dysfunction Effects 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
210000004777 protein coat Anatomy 0.000 description 1
238000011002 quantification Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

JP2460779A 1978-03-20 1979-03-05 Reagent with sugar for testing solid phase immunity Granted JPS54128396A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88805178A	1978-03-20	1978-03-20
US382779A	1979-01-16	1979-01-16

Publications (2)

Publication Number	Publication Date
JPS54128396A JPS54128396A (en)	1979-10-04
JPH02673B2 true JPH02673B2 (es)	1990-01-09

Family

ID=26672244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2460779A Granted JPS54128396A (en)	1978-03-20	1979-03-05	Reagent with sugar for testing solid phase immunity

Country Status (9)

Country	Link
JP (1)	JPS54128396A (es)
AU (1)	AU527489B2 (es)
DE (1)	DE2910707C2 (es)
ES (1)	ES478800A1 (es)
FR (1)	FR2420762A1 (es)
GB (1)	GB2016687B (es)
IT (1)	IT1113315B (es)
NL (1)	NL7902152A (es)
SE (1)	SE7902389L (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5622871A (en)	1987-04-27	1997-04-22	Unilever Patent Holdings B.V.	Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
JPS56141559A (en) *	1980-04-04	1981-11-05	Toray Ind Inc	Reagent for immunological inspection
GB2107053A (en) *	1980-06-20	1983-04-20	Unilever Plc	Processes and apparatus for carrying out specific binding assays
EP0146654A3 (en) *	1980-06-20	1986-08-20	Unilever Plc	Processes and apparatus for carrying out specific binding assays
JPS57208459A (en) *	1981-06-19	1982-12-21	Eisai Co Ltd	Measuring method using enzyme-labelled antibody and reagent
JPS58187861A (ja) *	1982-04-26	1983-11-02	Otsuka Pharmaceut Co Ltd	成人型ｔ細胞性白血病関連抗体の測定法
GB2124231B (en) *	1982-05-24	1985-10-02	Corning Glass Works	Solid phase reagent for immunoassay
JPS6035263A (ja) *	1983-08-05	1985-02-23	Wako Pure Chem Ind Ltd	不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
EP0133976A3 (de) *	1983-08-09	1986-07-30	F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft	Reagens für Immunverfahren
GB2187191B (en) *	1984-01-30	1989-11-01	Quadrant Bioresources Ltd	Protection of proteins and the like
EP0153875A3 (en) *	1984-03-01	1987-06-24	The State Of Victoria	Enzyme-linked immunosorbent assay method and test kit
GB8500698D0 (en) *	1985-01-11	1985-02-13	Unilever Plc	Preparation of reagents
DE3690028C2 (de) *	1985-01-15	1995-05-24	Cancer Res Inst	Verfahren und Testkit für die Analyse einer biologischen Probe auf Antikörper gegen Retroviren
GB8500918D0 (en) *	1985-01-15	1985-02-20	Cancer Res Inst	Viral isolates
JPH0779694B2 (ja) *	1985-07-09	1995-08-30	カドラントバイオリソ−シズリミテツド	蛋白質および同類品の保護
JPS6234059A (ja) *	1985-08-07	1987-02-14	Sankyo Co Ltd	固相化試薬の安定化剤
DE3856421T2 (de) *	1987-04-27	2000-12-14	Unilever Nv	Spezifische Bindungstestverfahren
GB8716826D0 (en) *	1987-07-16	1987-08-19	Tills D	Protection of proteinaceous reagents
ATE92633T1 (de) *	1988-05-11	1993-08-15	Abbott Lab	Verfahren zur erhoehung der spezifizitaet in kompetitiven immuntests.
AU2684488A (en)	1988-06-27	1990-01-04	Carter-Wallace, Inc.	Test device and method for colored particle immunoassay
AU609332B2 (en) *	1988-11-09	1991-04-26	Biotrack, Inc.	Method and composition of stabilizing and solubilizing latex reagents
US6352862B1 (en)	1989-02-17	2002-03-05	Unilever Patent Holdings B.V.	Analytical test device for imuno assays and methods of using same
US5998220A (en)	1991-05-29	1999-12-07	Beckman Coulter, Inc.	Opposable-element assay devices, kits, and methods employing them
US5877028A (en)	1991-05-29	1999-03-02	Smithkline Diagnostics, Inc.	Immunochromatographic assay device
US5468648A (en)	1991-05-29	1995-11-21	Smithkline Diagnostics, Inc.	Interrupted-flow assay device
US5869345A (en)	1991-05-29	1999-02-09	Smithkline Diagnostics, Inc.	Opposable-element assay device employing conductive barrier
US5607863A (en)	1991-05-29	1997-03-04	Smithkline Diagnostics, Inc.	Barrier-controlled assay device
GB9211176D0 (en) *	1992-05-27	1992-07-08	Central Blood Lab Authority	Assay
FI92882C (fi) *	1992-12-29	1995-01-10	Medix Biochemica Ab Oy	Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
US6319676B1 (en)	1995-05-02	2001-11-20	Carter Wallace, Inc.	Diagnostic detection device and method
US5879951A (en)	1997-01-29	1999-03-09	Smithkline Diagnostics, Inc.	Opposable-element assay device employing unidirectional flow
US5939252A (en)	1997-05-09	1999-08-17	Lennon; Donald J.	Detachable-element assay device
GB9925016D0 (en)	1999-10-23	1999-12-22	Univ Sheffield	Binding surface
KR20020070493A (ko) *	2000-11-20	2002-09-09	마쯔시다덴기산교 가부시키가이샤	체외 진단약
CA2544185C (en) *	2003-10-28	2010-09-28	Advanced Life Science Institute, Inc.	Method of detecting hepatitis c virus
US20050112687A1 (en) *	2003-11-25	2005-05-26	Jose Remacle	Method for stabilizing proteins on a micro-array
NL1027931C2 (nl) *	2004-12-31	2006-07-03	Univ Delft Tech	Werkwijze voor het vervaardigen van een chemische inrichting.
RU2446402C2 (ru) *	2006-10-24	2012-03-27	Конинклейке Филипс Электроникс Н.В.	Обнаружение целевых молекул в образце
US10024937B2 (en)	2011-09-27	2018-07-17	Koninklijke Philips N.V.	Gradient amplifier with compensation for dead time and forward voltage
US9492824B2 (en)	2013-01-16	2016-11-15	Sharp Kabushiki Kaisha	Efficient dilution method, including washing method for immunoassay

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1284947A (en) *	1969-05-27	1972-08-09	Abbott Lab	Improved lyophilized erythrocyte composition
US3790663A (en) *	1970-07-07	1974-02-05	Us Health	Preparation of dry antiserum coated solid-phase for radioimmunoassay of antigens
CH582884A5 (es) *	1973-12-10	1976-12-15	Hoffmann La Roche
SE7610683L (sv) *	1975-09-29	1977-06-10	Cordis Corp	Metod for bestemning av nervaron av ett antigen associerat med hepatit

1979
- 1979-02-13 GB GB7904984A patent/GB2016687B/en not_active Expired
- 1979-02-13 AU AU44195/79A patent/AU527489B2/en not_active Ceased
- 1979-03-05 JP JP2460779A patent/JPS54128396A/ja active Granted
- 1979-03-16 SE SE7902389A patent/SE7902389L/ not_active Application Discontinuation
- 1979-03-19 FR FR7906903A patent/FR2420762A1/fr active Pending
- 1979-03-19 DE DE2910707A patent/DE2910707C2/de not_active Expired
- 1979-03-19 IT IT21112/79A patent/IT1113315B/it active
- 1979-03-19 NL NL7902152A patent/NL7902152A/xx not_active Application Discontinuation
- 1979-03-20 ES ES478800A patent/ES478800A1/es not_active Expired

Also Published As

Publication number	Publication date
JPS54128396A (en)	1979-10-04
DE2910707A1 (de)	1979-10-04
AU4419579A (en)	1979-09-27
NL7902152A (nl)	1979-09-24
GB2016687A (en)	1979-09-26
IT1113315B (it)	1986-01-20
SE7902389L (sv)	1979-09-21
AU527489B2 (en)	1983-03-10
GB2016687B (en)	1982-09-08
DE2910707C2 (de)	1982-05-27
ES478800A1 (es)	1980-01-16
IT7921112A0 (it)	1979-03-19
FR2420762A1 (fr)	1979-10-19

Publication	Publication Date	Title
JPH02673B2 (es)	1990-01-09
US4497899A (en)	1985-02-05	Immunoassay for Chlamydia trachomatis antigens
Farci et al.	1983	Delta hepatitis in inapparent carriers of hepatitis B surface antigen: a disease simulating acute hepatitis B progressive to chronicity
Jongerius et al.	1998	New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays
US5147777A (en)	1992-09-15	Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use
Bradley et al.	1979	Serodiagnosis of viral hepatitis A by a modified competitive binding radioimmunoassay for immunoglobulin M anti-hepatitis A virus
US4474878A (en)	1984-10-02	Sandwich EIA for antigen associated with hepatitis
CA1148859A (en)	1983-06-28	Simultaneous assay of two hepatitis viruses using a solid phase
US5200315A (en)	1993-04-06	Particulate biologically active reagent containing polyoxyalkylene side chains, analytical element and methods for use of the reagent
US4642285A (en)	1987-02-10	Sandwich EIA for antigen
Moritsugu et al.	1975	Hepatitis B core antigen: detection of antibody by radioimmunoprecipitation
CN1300581C (zh)	2007-02-14	Sars病毒抗体检测方法及快速诊断试剂盒和制备方法
Eble et al.	1991	Differential diagnosis of acute viral hepatitis using rapid, fully automated immunoassays
JP2524101B2 (ja)	1996-08-14	Ｂ型肝炎に対する共通決定因子抗体の検出のための免疫決定法
Feinman et al.	1982	The significance of IgM antibodies to hepatitis B core antigen in hepatitis B carriers and hepatitis B‐associated chronic liver disease
Villa et al.	1981	Hepatitis B virus markers on dried blood spots. A new tool for epidemiological research
Dormeyer et al.	1981	The significance of serologic, histologic, and immunohistologic findings in the prognosis of 88 asymptomatic carriers of hepatitis B surface antigen
Moestrup et al.	1985	Hepatitis B virus‐DNA in the serum of patients followed‐up longitudinally with acute and chronic hepatitis B
Krogsgaard et al.	1986	Hepatitis B virus DNA in hepatitis B surface antigen-positive blood donors: relation to the hepatitis B e system and outcome in recipients
US5262297A (en)	1993-11-16	Specific binding analytical and separation methods using carboxy containing polymers
Koike et al.	1987	IgM anti‐HBc in anti‐HBe positive chronic type B hepatitis with acute exacerbations
WO1990015328A1 (en)	1990-12-13	Improved immunoassay
CA1086647A (en)	1980-09-30	Sugar coated reagents for solid phase immunoassay
Lipman et al.	1973	Isolation of cores from hepatitis B Dane particles
Fields et al.	1986	Experimental transmission of the delta virus to a hepatitis B chronic carrier chimpanzee with the development of persistent delta carriage